Aardvark Therapeutics (AARD) Current Assets (2024 - 2026)
Aardvark Therapeutics (AARD) posted Current Assets of $93.6 million for Q1 2026, down 16.36% sequentially from $111.9 million in Q4 2025, and down 39.45% YoY from $154.6 million in Q1 2025.
Aardvark Therapeutics (AARD) Current Assets (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Current Assets for 3 years, with the latest figure at $93.6 million in Q1 2026.
- Quarterly Current Assets fell 39.45% year-over-year to $93.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.6 million (down 39.45% YoY) and the FY2025 annual result came in at $111.9 million, up 50.92% from the prior year.
- Current Assets declined to $93.6 million in Q1 2026 per AARD's latest filing, from $111.9 million in the prior quarter.
- Over five years, Current Assets peaked at $154.6 million in Q1 2025 and troughed at $74.1 million in Q4 2024.
- A 3-year average of $118.0 million and a median of $120.5 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2025 and 2026: Current Assets surged 50.92% in 2025, then sank 39.45% in 2026.
- Over 3 years, Current Assets stood at $74.1 million in 2024, then soared by 50.92% to $111.9 million in 2025, then retreated by 16.36% to $93.6 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $93.6 million, $111.9 million, and $129.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 1.76 Bn |
| 10 | Aardvark Therapeutics | 142.55 Mn | 68.63 Mn | - | 80.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.66 Mn |
| Mar 31, 2026 | 93.58 Mn |
| Dec 31, 2025 | 111.89 Mn |
| Sep 30, 2025 | 129.21 Mn |
| Jun 30, 2025 | 144.77 Mn |
| Mar 31, 2025 | 154.55 Mn |
| Dec 31, 2024 | 74.14 Mn |